URGN - UroGen Pharma Ltd.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$42.50
DETAILS
HIGH:
$45.00
LOW:
$40.00
MEDIAN:
$42.50
CONSENSUS:
$42.50
UPSIDE:
47.11%
Profitability Ratios
| Ratio | Value |
|---|---|
| GP Margin | 88.7% |
| EBIT Margin | -125.8% |
| EBITDA Margin | -123.6% |
| Operating Margin | -113.7% |
| Pretax Margin | -139.7% |
| Cont. Ops Margin | -139.8% |
| Net Margin | -139.8% |
| Bottom Line Margin | -139.8% |
Liquidity Ratios
| Ratio | Value |
|---|---|
| Current Ratio | 4.01 |
| Quick Ratio | 3.65 |
| Solvency Ratio | -0.494 |
| Cash Ratio | 2.39 |
Valuation Ratios
| Ratio | Value |
|---|---|
| Price/Earnings |
-7.34
Peers avg: 18.0
|
| PEG Ratio | -0.94 |
| Forward PEG | -0.94 |
| Price/Book | -10.68 |
| Price/Sales | 10.26 |
| Price/FCF | -6.92 |
| Price/Op Cash Flow | -6.94 |
Debt Ratios
| Ratio | Value |
|---|---|
| Debt/Assets | 0.6402 |
| Debt/Equity | -1.2167 |
| Debt/Capital | 5.6143 |
| Long-Term Debt/Capital | 7.3022 |
| Financial Leverage | -1.90 |
Cash Flow Ratios
| Ratio | Value |
|---|---|
| Working Capital Turnover | 0.59 |
| Operating Cash Flow Ratio | -3.500 |
| Operating Cash Flow/Sales | -148.0% |
| Free Cash Flow/Operating Cash Flow | 100.2% |
Coverage Ratios
| Ratio | Value |
|---|---|
| Debt Service Coverage | -4.01 |
| Interest Coverage | -3.6889 |
| Short-Term Operating Cash Flow Coverage | 0.00 |
| Operating Cash Flow Coverage | -1.27 |
| Capital Expenditure Coverage | -562.09 |
| Dividend + Capital Expenditure Coverage | -562.09 |
Dividend Ratios
| Ratio | Value |
|---|---|
| Payout Ratio | 0.0000% |
| Dividend Yield | 0.0000% |
| Dividend Yield % | 0.0000% |
| Dividend Per Share | 0.0000 |
Per Share Ratios
| Ratio | Value |
|---|---|
| Revenue/Share | 2.28 |
| EPS | -3.190 |
| Debt/Share | 3.3706 |
| Cash/Share | 2.50 |
| Book Value/Share | -2.19 |
| Tangible BV/Share | -2.19 |
| Equity/Share | -2.19 |
| Operating Cash Flow/Share | -3.376 |
| Capital Expenditure/Share | 0.006 |
| FCF/Share | -3.382 |
Other Ratios
| Ratio | Value |
|---|---|
| Net Income/Earnings Before Tax | 1.001 |
| Earnings Before Tax/EBIT | 1.229 |
| Price/Fair Value | -10.68 |
| Debt/Market Cap | 0.1084 |
| Effective Tax Rate | -0.1% |
| Enterprise Value Multiple | -8.44 |